Celgene

Type	Subsidiary
Industry	Biotechnology
Founded	1986 (1986)
Founder	Sol J. Barer
Headquarters	Summit, New Jersey, U.S.
Key people	Robert J. Hugin (Executive Chairman) Mark Alles (CEO)
Products	Revlimid Abraxane Pomalyst/Imnovid Thalomid Idhifa
Revenue	$15.281 billion (2018)
Net income	$4.046 billion (2018)
Total assets	$35.480 billion (2018)
Total equity	$6.161 billion (2018)
Number of employees	8,852 (2018)
Parent	Bristol Myers Squibb
Website	www.bms.com

Celgene Corporation is a pharmaceutical company that makes cancer and immunology drugs. Its major product is Revlimid (lenalidomide), which is used in the treatment of multiple myeloma, and also in certain anemias. The company is incorporated in Delaware, headquartered in Summit, New Jersey, and a subsidiary of Bristol Myers Squibb (BMS).

For detailed contact information visit location pages below.